Sunshine Biopharma, Inc. (SBFMW) स्टॉक विश्लेषण

कंपनी का अवलोकन

Sunshine Biopharma, Inc. operates as a pharmaceutical entity dedicated to the research and development of life-saving medicines across various therapeutic areas, specifically targeting oncology and antivirals within the United States and Canadian markets. The company functions through segments including Prescription Generic Pharmaceuticals and Nonprescription products, though specific sector and industry classifications are not explicitly defined in available public data. The firm currently reports an annual revenue of $36.31 million over the trailing twelve months, while precise figures for market capitalization and employee count remain unlisted in the provided financial records. The absence of a disclosed market cap prevents a direct assessment of its total market valuation, yet the revenue figure of $36.31 million suggests a mid-sized operational scale focused on niche therapeutic development rather than broad-scale mass market dominance. This financial structure indicates a business model heavily reliant on R&D expenditures and regulatory approvals, typical of biopharma firms where revenue generation is often secondary to pipeline advancement in the short term.

वित्तीय स्वास्थ्य

The company reported a revenue of $36.31 million, a net income of -$5,975,352, and an EBITDA of -$4,146,712, highlighting a significant divergence between top-line sales and bottom-line profitability. The substantial gap between the positive revenue of $36.31 million and the negative net income reveals a cost structure where operating expenses, likely driven by R&D and general administration, exceed gross margins by a wide margin. Free cash flow stands at -$4,632,801, indicating that the company is currently burning cash rather than generating liquidity, which constrains its immediate financial flexibility and necessitates reliance on existing cash reserves or external financing. Gross margin is calculated at 33.8%, operating margin sits at -19.3%, and profit margin is -16.5%; these negative operating and profit margins demonstrate that the company is not yet profitable on an operational basis, a common characteristic during the development phase of pharmaceutical assets. The firm holds $9.12 million in cash against a debt obligation of $812,422, resulting in a debt-to-equity ratio of 3.53, which characterizes a highly leveraged balance sheet relative to its equity base despite the low absolute debt amount. The current ratio of 4.17 suggests a robust short-term liquidity position, as current assets are more than four times current liabilities, providing a buffer for meeting near-term obligations. Return on Equity is -25.7% and Return on Assets is -9.2%, metrics that indicate management is currently destroying shareholder value and utilizing assets inefficiently in terms of generating positive returns.

मूल्यांकन आकलन

Trailing P/E and forward P/E ratios are unavailable due to the company's negative earnings, rendering traditional earnings-based valuation multiples inapplicable for assessing expected earnings trajectory or future performance expectations. The price-to-book ratio is 0.02, indicating that the market values the company at a fraction of its net asset value, which often reflects high uncertainty regarding the recoverability of assets or the potential value of the pharmaceutical pipeline. Price-to-sales and EV/EBITDA multiples are not provided in the available facts, preventing a comparative analysis against peers using these alternative valuation metrics. The stock has traded between a 52-week high of $0.13 and a 52-week low of $0.13, meaning the current price is effectively trading at 0% below the 52-week high and at the floor of its recent trading range. With a beta of 1.60, the stock exhibits significant price volatility, moving 60% more than the broader market, which implies higher risk for investors seeking stability compared to large-cap pharmaceutical peers.

Growth & Income

Revenue growth year-over-year is -10.6%, while earnings growth is not applicable due to the company's lack of profitability; this contraction in revenue suggests a challenging market environment or potential decline in prescription volumes for its generic and nonprescription products. Since the company does not pay dividends, there is no dividend yield or payout ratio to evaluate for sustainability, as the firm instead retains its limited cash resources to fund ongoing research and development activities. The overall growth and income profile is characterized by negative revenue momentum and an absence of income distribution, reflecting a strategy prioritized on long-term asset development rather than immediate shareholder returns. This profile is typical for biopharma companies in the pre-commercialization or early commercialization stages, where capital preservation and pipeline expansion take precedence over revenue expansion and profit generation.